Long-Acting Drugs Market Projected to Reach $13.3 Billion by 2033, Driven by Chronic Disease Burden and Delivery Technology Innovation
核心洞察
The global long-acting drugs market is forecast to grow from US$ 7.2 billion in 2026 to US$ 13.3 billion by 2033, representing a compound annual growth rate of 8.9%.
Rising prevalence of chronic diseases including cancer (搜索), diabetes, HIV (搜索), and CNS disorders is accelerating demand for sustained-release therapies that reduce dosing frequency and improve adherence.
Eli Lilly's oral GLP-1 receptor (搜索) agonist orforglipron demonstrated superior A1C and body weight reduction versus oral semaglutide in Phase III trials, signaling a shift toward oral long-acting metabolic therapies.
The global long-acting drugs market is on a robust growth trajectory, expected to reach US$ 13.3 billion by 2033, up from an estimated US$ 7.2 billion in 2026, according to a new report from Persistence Market Research. The market is projected to expand at a compound annual growth rate (CAGR) of 8.9% over the forecast period, fueled by the escalating prevalence of chronic diseases, growing demand for patient-friendly therapeutic options, and rapid innovation in sustained-release drug delivery systems.
Long-acting formulations are gaining traction across multiple therapeutic areas — including oncology, diabetes, HIV (搜索), psychiatric disorders, and cardiovascular diseases — where maintaining consistent therapeutic levels is essential for effective long-term disease management.
Rising Chronic Disease Burden Drives Adoption
The worldwide surge in chronic conditions is a primary catalyst for market expansion. The World Health Organization reported nearly 20 million new cancer (搜索) cases globally in 2022, while diabetes now affects more than 500 million people worldwide. Conditions such as schizophrenia (搜索), HIV (搜索), and cardiovascular disorders similarly require prolonged treatment regimens where patient adherence remains a persistent challenge.
Long-acting formulations directly address non-adherence by reducing dosing frequency and sustaining stable drug concentrations over weeks or months. In psychiatric care, long-acting injectables and polymer-based depots are increasingly deployed to prevent treatment interruptions that can lead to hospitalization. In HIV (搜索) prevention, injectable cabotegravir has transformed adherence patterns by replacing daily oral regimens with bi-monthly dosing schedules.
"Pharmaceutical companies are responding with advanced formulations that enhance bioavailability, extend therapeutic action, and minimize side effects," the report notes, adding that investments in long-acting oncology and CNS therapies accelerated in 2025 as healthcare systems prioritized improved patient outcomes and lower treatment costs.
Eli Lilly's Orforglipron Marks a Pivotal Advance in Oral GLP-1 Therapy
A standout development in 2025 was Eli Lilly and Company's advancement of orforglipron, an oral GLP-1 receptor (搜索) agonist, following successful Phase III clinical trial results in diabetes and obesity (搜索) management. According to the company, the therapy demonstrated statistically significant improvements in blood sugar control and body weight reduction across multiple late-stage studies involving adults with type 2 diabetes (搜索) and obesity.
Orforglipron is a once-daily oral small-molecule GLP-1 receptor (搜索) agonist designed without food and water intake restrictions, a feature that differentiates it from existing oral GLP-1 treatments. In one Phase III study, the drug showed superior efficacy compared with oral semaglutide in reducing A1C and body weight.
Reuters reported that Eli Lilly expected obesity (搜索) trial results for orforglipron during 2025 as global demand for GLP-1 therapies continued to surge. The company aimed to pursue regulatory approvals following the positive trial outcomes. This development signals a broader transition toward patient-focused chronic disease therapies that prioritize ease of administration and long-term treatment adherence, and is expected to intensify competition within diabetes and obesity management markets.
Microsphere-Based Systems Dominate Delivery Technology
Among delivery technologies, microsphere-based systems hold the leading position due to their ability to provide controlled and sustained drug release, improving both therapeutic effectiveness and patient compliance. These biodegradable polymer particles gradually release active ingredients over weeks or months, significantly reducing dosing frequency in chronic disease treatments.
The technology is widely used across oncology, hormonal therapies, CNS disorders, and infectious disease management because of its versatility and compatibility with injectable formulations. Microspheres also improve drug stability, bioavailability, and targeted delivery while minimizing side effects. Strong regulatory familiarity, expanding clinical adoption, and continuous advancements in biodegradable polymer technologies further reinforce their market leadership.
The rise of oral long-acting biologics represents another transformative opportunity. Technologies employing permeation enhancers and protective coatings are enabling peptide-based therapies to survive gastric degradation and maintain bioavailability. Products such as oral semaglutide and next-generation GLP-1 therapies illustrate how sustained-release technologies are expanding beyond injectables. Manufacturers are also investing in sensor-enabled delivery systems and smart packaging solutions that improve dose tracking and patient monitoring.
Regional Dynamics: North America Leads, Asia Pacific Surges
North America holds the largest share of the long-acting drugs market, accounting for approximately 41.2% of global value. This leadership is supported by strong pharmaceutical R&D activity, advanced healthcare infrastructure, and favorable regulatory approvals. The United States dominates regional demand, driven by increasing adoption of long-acting injectables in oncology, diabetes, schizophrenia (搜索), and HIV (搜索) therapies. FDA approvals for sustained-release formulations and robust reimbursement policies continue to strengthen market expansion.
Asia Pacific is identified as the fastest-growing region, with China and India leading regional growth due to rising chronic disease prevalence, improving healthcare access, and expanding pharmaceutical manufacturing capabilities. Government healthcare initiatives and growing investments in drug delivery innovation are encouraging adoption of long-acting therapies across large patient populations.
Europe follows with strong growth supported by aging populations, increasing clinical trial activity, and investments in advanced drug delivery technologies. Regulatory support from the European Medicines Agency and funding initiatives focused on innovative therapeutics continue to strengthen the region's position.
Competitive Landscape
Leading players shaping the long-acting drugs market include Eli Lilly and Company, ViiV Healthcare, Johnson & Johnson, Novartis AG, and AstraZeneca plc. Eli Lilly is expanding its metabolic disease portfolio through advanced oral GLP-1 therapies and sustained-release drug delivery innovation. ViiV Healthcare focuses on long-acting HIV (搜索) prevention and treatment solutions, strengthening its position through injectable therapies. Johnson & Johnson continues investing in long-acting psychiatric therapies, particularly injectable antipsychotics for schizophrenia (搜索) management. Novartis is strengthening oncology-focused sustained-release formulations, while AstraZeneca is investing in biologic delivery technologies and strategic partnerships for cardiovascular and metabolic diseases.
Industry-wide strategies emphasize advanced delivery technologies, expansion of chronic disease portfolios, patient-centric formulations, and partnerships supporting innovation in sustained-release therapeutics.